Interpace Biosciences Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Interpace Biosciences are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Interpace Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Interpace Biosciences is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 3.4 M | |
| Total Cashflows From Investing Activities | -315 K |
Interpace |
Interpace Biosciences Relative Risk vs. Return Landscape
If you would invest (100.00) in Interpace Biosciences on December 24, 2024 and sell it today you would earn a total of 100.00 from holding Interpace Biosciences or generate -100.0% return on investment over 90 days. Interpace Biosciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Interpace, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Interpace Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Interpace Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Interpace Biosciences, and traders can use it to determine the average amount a Interpace Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IDXG |
Based on monthly moving average Interpace Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Interpace Biosciences by adding Interpace Biosciences to a well-diversified portfolio.
Interpace Biosciences Fundamentals Growth
Interpace OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Interpace Biosciences, and Interpace Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Interpace OTC Stock performance.
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 11.72 M | ||||
| Shares Outstanding | 4.27 M | ||||
| Price To Earning | (1.07) X | ||||
| Price To Book | 10.04 X | ||||
| Price To Sales | 0.10 X | ||||
| Revenue | 41.31 M | ||||
| EBITDA | (9.12 M) | ||||
| Cash And Equivalents | 1.86 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 9.44 M | ||||
| Debt To Equity | 6.55 % | ||||
| Book Value Per Share | (14.51) X | ||||
| Cash Flow From Operations | (8.72 M) | ||||
| Earnings Per Share | (3.12) X | ||||
| Total Asset | 38.43 M | ||||
| Retained Earnings | (172.59 M) | ||||
| Current Asset | 19.16 M | ||||
| Current Liabilities | 23.37 M | ||||
Things to note about Interpace Biosciences performance evaluation
Checking the ongoing alerts about Interpace Biosciences for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Interpace Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Interpace Biosciences is not yet fully synchronised with the market data | |
| Interpace Biosciences has some characteristics of a very speculative penny stock | |
| Interpace Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Interpace Biosciences currently holds 9.44 M in liabilities with Debt to Equity (D/E) ratio of 6.55, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Biosciences has a current ratio of 0.6, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Interpace Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Interpace Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Interpace Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Interpace to invest in growth at high rates of return. When we think about Interpace Biosciences' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 41.31 M. Net Loss for the year was (14.94 M) with profit before overhead, payroll, taxes, and interest of 17.95 M. | |
| Interpace Biosciences currently holds about 1.86 M in cash with (8.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 28.0% of Interpace Biosciences shares are held by company insiders |
- Analyzing Interpace Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Interpace Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Interpace Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Interpace Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Interpace Biosciences' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Interpace Biosciences' otc stock. These opinions can provide insight into Interpace Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |